Abstract Tendons regenerate poorly due to a dense extracellular matrix and low cellularity. Cellular therapies aim to improve tendon repair using mesenchymal stem cells and tenocytes; however, a current limitation is the low proliferative potential of tenocytes in cases of severe trauma. The purpose of this study was to develop a method useful in veterinary medicine to improve the differentiation of Peripheral Blood equine mesenchymal stem cells (PB-MSCs) into tenocytes. PB-MSCs were used to study the effects of the addition of some growth factors (GFs) as TGFβ3 (transforming growth factor), EGF2 (Epidermal growth factor), bFGF2 (Fibroblast growth factor) and IGF-1 (insulin-like growth factor) in presence or without Low Level Laser Technology (LLLT) on the mRNA expression levels of genes important in the tenogenic induction as Early Growth Response Protein-1 (EGR1), Tenascin (TNC) and Decorin (DCN). The singular addition of GFs did not show any influence on the mRNA expression of tenogenic genes whereas the specific combinations that arrested cell proliferation in favour of differentiation were the following: bFGF2 + TGFβ3 and bFGF2 + TGFβ3 + LLLT. Indeed, the supplement of bFGF2 and TGFβ3 significantly upregulated the expression of Early Growth Response Protein-1 and Decorin, while the use of LLLT induced a significant increase of Tenascin C levels. In conclusion, the present study might furnish significant suggestions for developing an efficient approach for tenocyte induction since the external administration of bFGF2 and TGFβ3, along with LLLT, influences the differentiation of PB-MSCs towards the tenogenic fate.
Introduction
Tendons are made of dense connective tissue and present low cellularity and low vascularity. These properties confer characteristics such as stiffness and elasticity (Brehm et al. 2012; Smith et al. 2013; Patruno and Martinello 2014) , which are essential in transmitting forces between muscles and bones (Freedman et al. 2014) . However, the not-vascularized nature and low number of tenocytes, reduce the self-healing and regenerative potential of tendons (Jiang et al. 2014; Veronesi et al. 2015) . In veterinary medicine, several therapies are used to improve tendon regeneration although long rehabilitation periods are needed and relapses are frequent (Riley 2008; Spaas et al. 2012) . In order to augment tendon healing, innovative techniques are being used to treat tendon lesions, including tissue engineering and cell therapies (Delincé and Ghafil 2012) such as platelet-rich plasma (PRP), growth factors (GFs) (Maia et al. 2009 ), mesenchymal stem cells (MSCs) (Brehm et al. 2012 ) and low level laser irradiation (LLLI) (Sperandio et al. 2014; Iacopetti et al. 2015) . Since it should exists a synergy action between GFs present in PRP and Marco Patruno and Jan Spaas Contributed equally.
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PRP is an important source of autologous GFs (Abate et al. 2012 ) such as PDGF (Platelet-Derived Growth Factor), VEGF (Vascular endothelial growth factor), thromboxane, fibronectin/vitronectin, TGFβ (transforming growth factor), EGF (Epidermal growth factor), FGF (Fibroblast growth factor) (Anitua et al. 2015) , IGF (insulin-like growth factor) (Schär et al. 2015) and cell fractions that can accelerate wound healing, decrease the inflammatory reaction and promote regeneration of affected tissues (Dimauro et al. 2014) . In horses autologous platelet concentrates (APCs) are recently intensively studied in order to find the most appropriate protocols for clinical purposes (Hessel et al. 2015) . Moreover, it has been demonstrated that several GFs, such as EGF, bFGF, PDGF-BB and TGF-β1, influence tenogenic differentiation and extracellular matrix production (Goncalves et al. 2013) .
MSCs can be isolated from several sources (Martinello et al. 2010; Martinello et al. 2011; Zhu et al. 2013 , Toupadakis et al. 2010 , are able to generate several types of mature and differentiated cells and to improve tendinopathy treatment (Smith et al. 2013) . In equine medicine, bone marrow and peripheral blood are commonly used (Crovace et al. 2010; Martinello et al. 2013; Broeckx et al. 2014a Broeckx et al. , 2014b . MSCs isolated from horse peripheral blood (PB-MSCs) are able to differentiate into diverse mesenchymal lineages and could be used in cell-based therapies for the treatment of tendon, ligament, and bone pathologies as well as cartilage defects (Koerner et al. 2006; Giovannini et al. 2008; Martinello et al. 2010; Martinello et al. 2011; Spaas et al. 2013; Barberini et al. 2014) .
LLLT is a therapy being used by veterinarians to reduce inflammation and pain and accelerate tissue healing (Hawkins and Abrahamse 2006) . In vivo and in vitro studies have demonstrated the stimulatory capacity of low-level laser energy on cell populations obtained from different tissues (Posten et al. 2005) . Chen et al. (2015) showed that LLLT is able to stimulate proliferation and collagen synthesis of tenocytes as well as keratinocyte proliferation. Pyo et al. (2013) demonstrated that LLLI increase cell proliferation and promote the expression of BMP-2, osteocalcin, and TGFβ1 hypothesizing an influence in bone regeneration through a stimulatory effect on osteoblasts favouring their growth and maturation.
Although these new treatments have shown some positive effects on tendon regeneration, researchers are starting to combine different strategies to improve tendon regenerative capabilities. Another recent approach for enhancing tendon regeneration is the tenogenic induction of MSCs before clinical use. Using this methodology, Pietschmann et al. (2013) showed that tenocytes demonstrated increased biomechanical and histologic regenerative properties in a full-size tendon defect when compared to non-induced MSCs. Unfortunately, autologous tenocytes have a limited proliferative potential and ethic committees from many countries prohibit invasive collection of tendon tissue to obtain tenocytes (Tan et al. 2012) . Our hypothesis was to evaluate the synergic action of GFs, usually present in PRP preparations, and LLLT for inducing the differentiation of low immunogenic MSCs (Broeckx et al. 2014a (Broeckx et al. , 2014b towards the tenogenic fate; therefore, we have used different combinations of GFs, with and without LLLT, in order to check the gene expression of EGR1 (Early growth response protein 1), Tenascin C (TNC) and Decorin (DCN), all crucial genes involved in tenogenesis (Pajala et al. 2009; Tao et al. 2015; Dunkman et al. 2013 ).
Materials and methods

Isolation and culture of PB-MSCs
Twenty millilitres of blood were collected into sterile EDTA (Ethylenediaminetetraacetic acid) tubes from the external jugular vein of four adult mares between five and seven years of age. Animal Ethics Committee approval numbers and date are: EC_2012_001 (21-11-2012) and EC_2014_001, (17-02-2014) by Global Stem Cell Technology, GST, Belgium; EC_2014_020 (07-04-2014) by Faculty of Veterinary Medicine, Ghent University, Belgium.
Blood samples were transported to the GST-ANACURA laboratory at room temperature within 4 h of sampling. Blood samples were centrifuged at 1000 g for 20 min at room temperature (RT) and the buffy coat collected and diluted 1:2 with Phosphate Buffered Saline (PBS). The cell suspension was layered on Percoll gradient (density 1.080 g/mL; GE Healthcare) and centrifuged at 600 g for 15 min at RT. The interphase was collected, washed three times with PBS and centrifuged at 200 g for 10 min at RT (Spaas et al. 2013) . The putative MSCs were seeded in a T75 flask (BD Falcon) with an expansion medium (Exp) made as follows: Dulbecco's Modified Eagle Medium (DMEM, Euroclone ECM0728L), 20 % fetal calf serum (FCS, (Euroclone ECS0180L), 1 % antibiotics/antimycotics (Euroclone ECB3001D) and 10 −11 M dexamethasone (Sigma Aldrich). The medium was refreshed twice a week and cells cultured at 37°C and 5 % CO 2 . At 70 % of confluence, the cells were trypsinized with 0.25 % trypsin-ethylenediaminetetraacetic acid (Euroclone ECB3051D) passage 0 (P0) and further cultured for 10 additional passages (P1 → P10) with the same medium, but without dexamethasone (Sigma Aldrich). Cells were used at specific passages (P1-P10 for PDT experiment, P5 and P10 for Flow cytometry and P5 for GF and laser experiments) as described below.
Population doubling time (PDT)
PDT was calculated from P1 to P10 using the following formula: PDT = cell culture time (T)/cell doubling time (CDT). T was expressed as days from Ni to Nf, where Ni is the initial and Nf the final number of cells for each passage and CDT was obtained with the following formula: CDT = ln(Nf/Ni)/ ln(2) (Hoynowski et al. 2007 ).
Flow cytometry
For quality control purposes, immunophenotypic characterization (Spaas et al. 2013 ) of all donor PB-MSCs was performed at P5 and P10. Briefly, PB-MSCs were tested for the stem cell Cluster of Differentiation (CD) markers CD29, CD44 and CD90 and for the adult blood cell (negative) markers CD45, major histocompatibility complex (MHC) type II and monocyte/macrophage marker by flow cytometry. The cells were prepared as described in Spaas et al. (2013) . 
Addition of growth factors (GFs)
PB-MSCs obtained from four donor horses were seeded, at passage 5, each in T25 flasks (1500 cells/cm 2 ) to test the effects of the addition of some growth factors (GFs) on the mRNA expression levels of genes important in the tenogenic induction such as EGR1, TNC and DCN (see below the Real Time PCR method). The GFs added were the following: TGFβ3 (transforming growth factor), EGF2 (Epidermal growth factor), bFGF2 (Fibroblast growth factor) and IGF-1 (insulin-like growth factor). The latter GFs were tested singularly with and without LLLT (data not shown) in order to confirm previous observations (Schneider et al. 2011 ) that described no changes when GFs were tested alone. However, our preliminary results indicated that bFGF2 increased, although not significantly, the expression of the tested genes; consequently, and also because bFGF2 is essential in the tenogenic differentiation and wound repair, it has been decided to always use it in the following GFs combinations (see the panel below).
Combination
Growth factors The expansion medium (Exp) was therefore used alone (combination N.1) or with LLLT (combination N.2) or supplemented with: bFGF2 (combination N.3), bFGF2 and LLLT (combination N.4), bFGF2 and TGFβ3 (combination N.5), bFGF2, TGFβ3 and LLLT (combination N.6), bFGF2 and IGF1 (combination N.7), bFGF2, IGF1 and LLLT (combination N.8), bFGF2 and EGF2 (combination N.9), bFGF2, EGF2 and LLLT (combination N.10). All GFs are by Sigma-Aldrich and were added to the medium at 10 ng/ml. PB-MSCs were cultured in duplicate to evaluate the effect of the GFs treatment alone and in addition to LLLT. Cells were cultured in supplemented media for five days, with the medium refreshed at day three. Five days after seeding cells reached 70 % confluency and were trypsinized, counted and frozen at −80°C with 90 % expansion medium with 10 % DMSO (Dimethyl sulfoxide) for subsequent Real Time polymerase chain reaction (Real time-PCR) analyses. These experiments were repeated four times.
Low level laser technology (LLLT)
PB-MSCs seeded at 1500 cells/cm2 in T25 flasks were conditioned with GFs, as previously described in the paragraph above, and submitted to LLLT (ASAlaser, M6 handpiece) equipped with combined, synchronized and overlapping continuous and pulsed emissions emitted by a single handpiece. The emission was produced by an InGa(Al)As diode laser with the following parameters: for continuous wave the wavelength was of 660 nm while for pulsed laser diode the wavelength was of 905 nm (peak optical power 25 W). A daily dose of 5 J/cm 2 for 2 min performed by the same operator. The first irradiation was performed 24 h after seeding to allow cell attachment and conditioning of GFs. Subsequently, LLLT was performed once a day up to the fifth day after seeding; when cells reached 70 % of confluence they were trypsinized, counted and frozen.
Cell count
Cells were trypsinized and collected after each treatment with GFs and LLLT. The number were determined by Burker chamber counting and the cells were marked with Trypan Blue (Sigma B-7021) in order to calculate the average number of dead and live cells. This evaluation allowed discerning the effect of treatments between the arrest of proliferation and cell death.
RNA isolation and gene expression analysis
Total RNA extraction was performed using TRIzol (Life Technologies) reagent following the manufacturer's instructions. RNA was quantified on a Nanodrop (Thermo Scientific) spectrophotometer and a complementary single strand DNA (cDNA) was synthesized from 2 μg of purified RNA to perform real time-PCR using the ABI 7500 Real Time PCR system (Applied Biosystem). The relative expression of the following genes was used to evaluate tenogenic induction after five days of treatments: EGR1, DCN and TNC. Each sample was tested in triplicate and untreated PB-MSCs were used as a calibrator sample. The 2 -ΔΔct method was used to analyze and normalize the RNA expression of the target genes with respect to the endogenous housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). PCR primers were designed using Primer Express 3.0 software (Applied Biosystems).
Statistical analysis
Normally distributed data were expressed as the mean ± standard deviation. Normality of the data was confirmed using the Kolmogorov-Smirnov test (α = 5 %). Statistical analyses were performed using the paired Student t test (SPSS software, version 11.0, SPSS, IBM). The level of statistical significance was set at P ≤ 0.05 for all analyses.
Results
Flow cytometric analysis of isolated PB-MSCs
PB-MSCs were successfully isolated from peripheral blood of four healthy horses. The expression profile of cell-surface antigen in adherent PB-MSCs was evaluated by flow cytometry in cell samples at P5 (Fig. 1a) and P10 (Fig. 1b) . Cells from the four horses were uniformly positive for adhesion markers CD29 (100 % ± 0 at P5 and P10), CD44 (92 % ± 4 at P5, 99.3 % ± 0.5 at P10) and CD90 (100 % ± 0 at P5 and P10). In addition, the analysis demonstrated less than 5 % positivity for the hematopoietic lineage marker as CD45 (1.7 % ± 0.6 at P5, 1.2 % ± 0.3 at P10), for the leukocytes markers Mo/Ma (0.8 % ± 0.3 at P5, 1.4 % ± 2 at P10) and for the MHCII (0 % ± 0 at P5 and P10). In Fig. 1c , the CD percentages of different markers used in the study are summarized.
Population doubling time of isolated PB-MSCs
To examine PDT of PB-MSC samples (n = 4), the proliferation potential was measured according to the passage number (from P1 to P10). The PDT showed an initial lag time (supplemental figure), but PDT was relatively constant from P3 until P10. Figure 2 shows the concentration of dead cells (dark grey bars) and live cells (light grey bars) detected in cell culture after each treatment. All combination of GFs caused the same cytotoxicity (dead cells 31.5 ± 14.2, Fig. 2 ) and it was slightly greater than control medium and laser treatment. The combinations of bFGF2 + TGFβ3 and bFGF2 + TGFβ3 + LLLT, arrested cell proliferation compared to control cells and other GFs treatments (Fig. 2 light grey bars) without increasing the cell death. This data indicate that TGFβ3 influences the proliferation of MSCs, while EGF2 and IGF1 do not modify cell growth.
Cell proliferation of PB-MSCs treated with GFs and LLLT
MRNA expression of EGR1, TNC and DCN
PB-MSCs were used to test the effects of the addition of some GFs (TGFβ3, IGF1, bFGF2 and EGF2) on the mRNA expression levels of genes involved in the tenogenic differentiation such as EGR1, TNC and DCN. TGFβ3, IGF1, bFGF2 and EGF2 were previously tested individually with and without LLLT (data not shown) without obtaining any significant results; therefore, we started to use combinations of GFs with and without LLLT (see panel in the material and methods). Figure 3a and 3c indicate that EGR1 and DCN expression, respectively, increased significantly in the presence of bFGF2 and TGFβ3 with and without LLLT treatment (combination n. 5). The level of the TNC gene (Fig. 3b) appears to be influenced by treatment with bFGF2, TGFβ3 and LLLT (combination n. 6) since its expression increased significantly, Fig. 1 Detection of Cluster of Differentiation (CD) markers of peripheral blood cells using a flow cytometry assay. Peripheral Blood-MSCs (PBMSCs) tested at P5 (a) and P10 (b) showed a positivity for antibodies against CD29, CD44 and CD90 (in blue) and a negativity for Mo/Ma, MHCII and CD45 (in red). The table shows the average expression ± standard deviation of CD positivity and negativity of PB-MSCs at P5 and P10. Control isotypes were tested for each marker to define the threshold whereas, treatment with bFGF2 and TGFβ3 without LLLT showed a similar, but not-significant increasing trend. The factors bFGF2-EGF2 and bFGF2-IGF1 did not cause variations in EGR1, DCN and TNC mRNA levels in comparison to control PB-MSCs (Table 1) .
Discussion
Novel treatments used for tendon regeneration include PRP, MSCs and LLLT. Unfortunately, these methods do not typically result in complete healing of injured tendons and a return to total function is very difficult to achieve (Liu et al. 2011) . Obtaining in vitro functional tenocytes from MSCs is important for tissue healing and engineering applications (Bi et al. 2007; Tan et al. 2012) . We have hypothesized that a specific mixture of GFs in combination with LLLT induced the differentiation of MSCs towards a tenogenic fate.
The MSCs used in this study were obtained from peripheral blood (PB) of healthy horses (n = 4) and the cells were subjected to flow cytometric analysis for characterization. In the present study it was chosen to use the allogeneic PB-MSCs between P5 and P10 due to the insufficient cell yield at earlier passages and in order to generate multiple doses and perform all necessary quality assessments (Broeckx et al. 2014c; Vandenbergh et al. 2016) .
PB-derived MSCs showed a positive expression for adhesion and the MSC markers CD29, CD44 and CD90, both at passage P5 and P10. In contrast, PB-MSCs were not positive for the hematopoietic lineage marker CD45, the monocyte/ macrophage (Mo/Ma) leukocyte markers and MHC II. The present results showed that PB-MSCs did not lose their stem markers and the cells maintained their proliferative capacity through P10 after an initial lag phase.
In experimental studies conducted in vivo, LLLT produced an anti-inflammatory effect by decreasing the number of fibroblasts and neovascularization in tendon lesions of sheep Fig. 2 The histogram shows the average ± SD of the cell number counted after different treatments. The number of alive cells is rapresented by light grey bars while the number of dead cells is indicated by dark grey bars. The treatments did not modify the cell mortality while influenced the proliferation activity. Asterisk indicates significant differences (*P < 0.05) Fig. 3 mRNA expression of EGR1 (early growth response protein 1), TNC (tenascin c) and DCN (decorin) in PB-MSCs before treatment (Exp) and after different treatments (Exp L: laser treated cells; F: bFGF2; FL: bFGF2 + laser; FT: bFGF2 + TGFβ3; FTL: bFGF2 + TGFβ3 + laser; FI: bFGF2 + IGF1; FIL: bFGF2 + IGF + laser; FE: bFGF2 + EGF2; FEL: bFGF2 + EGF2 + laser) detected by Real-Time PCR. Each graph rappresents the average ± SD of cells isolated from four hoses and Exp sample was used as calibrator. Asterisk indicates significant differences (*P < 0.05) included in the study (Iacopetti et al. 2015) . In addition, LLLT used on tendinopathies in rats reduced the mRNA expression of pro-inflammatory mediators such as TNFa (tumor necrosis factors), IL1b and IL6 (interleukin), and TGFβ (Pires et al. 2011) . It is important to precise here that in vivo studies include many variables and, therefore, the contribution of LLLT is very difficult to understand. In vitro Huertas et al. (2014) observed a correlation between the energy density applied and cell growth rate while Pyo et al. (2013) attributed an increase in osteoblastic BMP2 (bone morphogenetic protein) and TGFβ1 expression to LLLT. In the latter study, it is possible to comment that LLLT induces a general increase of the superfamily TGF-β (BMPs are a subfamily of TGF-β) because it probably stimulates cell proliferation in regenerative processes. Surely, diverse energy densities differently stimulate cellular metabolic processes (i.e. increasing the oxidation, as discussed by Hamblin and Demidova 2006) and in our in vitro experiments a density that should influence cellular proliferation/differentiation was used, as previously observed in myoblasts (Monici et al. 2013) . Several studies have demonstrated the involvement of bFGF2 in regulating cell growth and differentiation (Hoffmann and Gross 2007) . In this regard, Cai et al. (2013) indicated that bFGF2 is able to activate the MAPK pathway promoting the differentiation of MSCs into tendons. In fact, the expression of bFGF2 induced tendon matrix protein collagen type I, collagen type III and scleraxis expression. Furthermore, it was demonstrated that bFGF2, introduced with a viral vector, modulated the expression of genes for multiple GFs, increased the gene level of TGF-β1, CTGF and VEGF and down-regulated IGF1 during the tendon repair process (Tang et al. 2014) . Overall, bFGF2 has been reported as the most potent growth stimulator among the various GFs (Takehara 2000) and it also plays a pivotal role in wound repair (Molloy et al. 2003) . However, in the present study, bFGF2 alone was not sufficient to induce a significant increase of expression of EGR1, TNC and DNC. Therefore, we evaluated the synergic action of bFGF2 in combination with TGFβ3, IGF1 or EGF2 to promote an increase of those tenogenic genes. TGFβ is a well-known cytokine that regulates various processes in tendon healing. Increased TGFβ levels are associated with tendon adhesion (Khan et al. 2000) as well as t e n d i n o s i s ( F u e t a l . 2 0 0 2 ) . T G F β i s a m a j o r anti-proliferative and pro-differentiation signal for hematopoietic stem/progenitor cells (Zhao and Chen 2014) . Decreased TGFβ expression reduces migration and proliferation of keratinocytes (Hameedaldeen et al. 2014 ) and the addition of TGFβ decreases the number of tendon sheath, epitenon and endotenon cells in culture (Klein et al. 2002) . Our results confirm the anti-proliferative activity of TGFβ3 in PB-MSCs. In fact, this GF decreased significantly the cellular proliferation but it did not modify cell death respect other GF treatments. The activation of a mechanism of cellular differentiation of PB-MSCs towards the tenogenic fate is hypothesized. Moreover, our results are supported by Rider et al. (2008) , which demonstrated that TGFβ3 inhibits endogenous bFGF activity for human adipose stem cells (hASCs) proliferation. In 3D culture this GF increased the expression of TNC, COL1 (collagen 1), COMP (cartilage oligomeric matrix protein) and Tenomodulin (Barsby et al. 2014) .
For the first time in equine MSCs, the genes EGR1, TNC and DCN were evaluated with the exogenous addition of GFs.
TGFβ3, IGF1 and EGF2 were tested individually (data not shown) but, as described by Schneider et al. (2011) , were not able to increase genes involved in the tenogenic pathway.
On the contrary, the combination of bFGF2 and TGFβ3 significantly upregulated the expression of EGR1 and DCN while the use of LLLT induced a significant increase in TNC levels. The EGR1 is one of the first transcription factors involved in the tenogenic cascade; it is associated with increased collagen formation during embryonic tenogenesis and induces Scleraxis (SCX) and Col1a1 genes (Lejard et al. 2011) . TNC although rarely present in most adult tissues is upregulated in embryonic and developing tissues or in tissues experiencing a fast rate of growth and influences cell adhesion and migration (Goncalves et al. 2013) . DCN is a proteoglycan that regulates tendon structure by stabilizing and aligning collagen fibrils (Zhang et al. 2006) .
The combination of bFGF2-IGF1 and bFGF2-EGF2 did not alter the expression of EGR1, TNC and DCN in treated PB-MSC versus control cells. In this case, the addition of LLLT to GF treatments did not promote the stimulation of EGR1, DCN and TNC tendon markers. Moreover, the combination bFGF2-IGF1 and bFGF2-EGF2 induced a level of proliferation activity similar to untreated MSCs, although IGF1 and EGF2 are known for their proliferative and differentiating effects. EGF2 is a single-chain polypeptide that has the ability to enhance migration and cell proliferation of bone marrow derived MSCs (Tamama et al. 2006) , and has been well documented for its mitogenic and chemotactic effects on fibroblasts (Brown et al. 1991) . Regarding IGF1, it is known that it has a stimulating effect on collagen synthesis in tendon-ligament tissue since it stimulates fibroblast proliferation and synthesis of extracellular matrix protein (Durgam et al. 2012; Hansen et al. 2013) . Most likely, in our study, the effect of IGF1 on tenogenic induction was not seen because the use of bFGF2 treatment might have down-regulated its expression (Tsubone et al. 2004 ).
Conclusions
The effects of GFs on cell cultures are conditioned by numerous variables, such as concentration and timing of incubation, combination of GFs, evaluated markers and cell type. However, we consider that this study might furnish significant suggestions for developing an efficient approach for tenogenic induction since from our results, the external administration of bFGF2 and TGFβ3, along with LLLT, surely optimize and accelerate the differentiation of PB-MSCs.
